Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Paion Says More Remimazolam Partnerships Possible in 2014

Nov. 7 (Bloomberg) -- Paion AG, a German drugmaker whose shares have more than doubled this year, may enter further partnerships to sell its Remimazolam sedative, Chief Executive Officer Wolfgang Soehngen said.

“We’re in talks, and are increasingly seeing more interested parties,” Soehngen said in an interview yesterday. “We don’t expect to reach a deal this year.”

A partnership would expand Remimazolam’s potential reach beyond the countries in which Paion already has agreements for the experimental product. The Aachen-based company’s stock has risen about 75 percent since announced licensing deals last week with R-Pharm in Russia and Hana Pharm Co. in South Korea.

The sedative is partnered in China with Humanwell Healthcare Group Co. “These deals allow us to benchmark the value of any future agreements,” Soehngen said.

Paion rose 5.6 percent to close at 1.995 euros in Frankfurt, giving the company a market value of 50.6 million euros ($67.8 million).

The stock has risen 139 percent this year. It pared gains yesterday after Paion said it lost 3.5 million euros in the first nine months of the year, compared with a 15.8 million euro profit a year earlier, when the company benefited from the sale of the Desmotoplase drug to H. Lundbeck A/S for 20.1 million euros.

To contact the reporter on this story: Eva von Schaper in Munich at

To contact the editor responsible for this story: Phil Serafino at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.